AFME.PA Affluent Medical EURONEXT 10 Feb 2026: €3.70 on heavy volume, watch

AFME.PA stock surged intraday to €3.70, a +31.67% move on a volume spike of 248,488 shares on EURONEXT (Europe). The stock opened at €3.70, hit a day high of €4.34 and traded well above its 50-day average of €1.78, signaling a large liquidity event. Traders noted a relative volume of 6.64, with average daily volume at 27,900 shares. We run through technicals, fundamentals, Meyka AI grading and short-term price guidance for high-volume movers.

Intraday price and liquidity details for AFME.PA stock

AFME.PA stock closed intraday at €3.70, up €0.89 or 31.67%, with a day range €3.46–€4.34. Market capitalization stands at €110,426,855.00 and shares outstanding are 39,297,813.00. Volume of 248,488.00 versus avg volume 27,900.00 produced a relative volume of 6.64, confirming heavy retail or block activity. The intraday move pushed price above the reported year high of €2.95, creating a near-term resistance breakout scenario.

Technical picture and momentum for AFME.PA stock

Momentum indicators show strength: RSI 64.09 and ADX 34.62 indicate a strong intraday trend. MACD is positive (MACD 0.10, Signal 0.07) with a small histogram 0.03. Volatility measures: ATR 0.13 and Bollinger middle €1.64, upper €2.08. On‑balance volume and MFI (79.38) confirm heavy buying pressure. Short-term traders should watch the €4.34 intraday high as resistance and €3.46 as initial support.

Fundamentals and valuation context for AFME.PA stock

Affluent Medical SA operates in Healthcare, Medical – Devices, with 66 employees and products for vascular and cardiac conditions. Key financials: EPS -0.36, reported PE -7.81, price-to-sales 23.52, price-to-book 5.24, and debt-to-equity 1.11. Current ratio is 1.07, and cash per share is €0.14. Compared with the Healthcare sector average PE 34.37, AFME.PA shows loss-making metrics and high multiples, underlining growth-stage risks.

Meyka AI grade and forecast for AFME.PA stock

Meyka AI rates AFME.PA with a score out of 100. Meyka AI rates AFME.PA with a score of 61.41 / 100 — Grade B — Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly €1.92, quarterly €2.27, and yearly €1.56. Compared with the current €3.70, those projections imply short-to-medium term downside: monthly -48.11%, quarterly -38.65%, yearly -57.82%. Forecasts are model-based projections and not guarantees. These grades are not guaranteed and we are not financial advisors.

Catalysts, risks and sector outlook for AFME.PA stock

Near-term catalysts include regulatory updates, clinical data or partnership announcements for AFFLUENT products (Kardiozis, Kalios, Epygon, Artus). Primary risks: continued operating losses, high receivables days (325.12) and tight cash runway at the current burn. Healthcare sector performance is muted (YTD -1.40%) and investors should weigh device commercialization risk against potential upside from successful trials.

High-volume trading strategy and price targets for AFME.PA stock

For intraday and swing traders: treat the move as a liquidity event. Short-term target: €4.50 (near resistance above day high €4.34). Medium-term model-based target: €2.27 (quarterly forecast), and conservative annual model target: €1.56. Stop-loss guidance: initial support at €3.46, tighter intraday risk control below €3.00. Position size should reflect high volatility and elevated price-to-sales and price-to-book multiples.

Final Thoughts

AFME.PA stock posted a clear high-volume breakout intraday to €3.70, with volume 248,488.00 and relative volume 6.64, signalling strong short-term interest on EURONEXT. Technicals favour momentum but fundamentals show loss-making metrics: EPS -0.36, PE -7.81, PB 5.24 and price-to-sales 23.52. Meyka AI’s forecast model projects quarterly €2.27 and yearly €1.56, implying downside of -38.65% and -57.82% versus the current price. Short-term traders can target €4.50 but must accept elevated risk; longer-term investors should weigh commercialization milestones and cash dynamics. Remember that Meyka AI’s forecasts are model-based projections and not guarantees. Use stop-loss discipline and confirm any catalyst or regulatory update before adding exposure. For company filings and background see the official site and data sources below.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.